Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | GALK1 | P51570 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | KDM4A | O75164 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 3/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180986 | 0.70 | TDP2 (1.00) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL2180811 | 0.66 | TDP2 (0.77) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL3473947 | 0.66 | TDP2 (0.65) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL3470636 | 0.66 | TDP2 (0.65) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL2181779 | 0.65 | TDP2 (1.00) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL3471248 | 0.65 | TDP2 (0.63) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL13272699 | 0.65 | TDP2 (0.70) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL3472993 | 0.64 | KDM4C (1.00) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL14614428 | 0.64 | TDP2 (0.57) | KDM4CNPC1POLBMAPTRAB9A | |
| SCHEMBL15032586 | 0.64 | TDP2 (1.00) | KDM4CNPC1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427032-B | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | Escend Pharmaceuticals, Inc. | 2024-10-17 | — | — | US | claimed |
| CN-118652994-A | Primer combination, detection method, detection product and application of detection product | 深圳市宝安区疾病预防控制中心(深圳市宝安区卫生检验中心、深圳市宝安区职业病防治所) | 2024-09-17 | — | — | CN | claimed |
| EP-3500686-B1 | METHODS FOR DETECTING CRANIOPHARYNGIOMA AND FOR SELECTING MEDICAMENTS AND PATIENTS FOR TREATMENT | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| EP-3784240-B1 | WNT6 AS GLIOBLASTOMA ONCOGENIC BIOMARKER, AND USES OF INHIBITORS THEREOF FOR TREATING WNT6-OVEREXPRESSING GLIOBLASTOMA | UNIV DO MINHO (PT) | 2023-09-20 | — | — | EP | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-20230049309-A1 | CATHETER DEVICE FOR RELEASING PHARMACEUTICALLY ACTIVE COMPOUNDS OVER AN EXTENDED PERIOD | CIRLO GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| CN-105974018-B | Method based on Multifunctional cleanup column-high performance liquid chromatography detection sitotoxismus flavine | 浙江省产品质量安全检测研究院 | 2018-06-12 | — | — | CN | claimed |
| CN-105319313-B | Liquid chromatogram-tandem mass spectrum detection method of toxoflavin | 山东出入境检验检疫局检验检疫技术中心 | 2017-02-01 | — | — | CN | claimed |
| CN-106018659-A | Method for quick detection of toxoflavin in food | 浙江省质量检测科学研究院 | 2016-10-12 | — | — | CN | claimed |
| CN-105974018-A | Method for detecting toxoflavin in foodstuff based on multifunctional purifying column-high performance liquid chromatography | 浙江省质量检测科学研究院 | 2016-09-28 | — | — | CN | claimed |
| CN-105319313-A | Liquid chromatogram-tandem mass spectrum detection method of toxoflavin | SHANDONG TECHNICAL CT INSPECTION & QUARANTINE | 2016-02-10 | — | — | CN | claimed |
| US-20100269215-A1 | Tfla gene which can degrade toxoflavin and its chemical derivatives and transgenic organisms expressing tfla gene | SNU R&DB FOUNDATION (KR) | 2010-10-21 | — | — | US | claimed |
| CN-101578360-A | tflA gene which can degrade toxoflavin and its chemical derivatives and transgenic organisms expressing tflA gene | SEOUL NAT UNIV IND FOUNDATION (KR) | 2009-11-11 | — | — | CN | claimed |
| EP-2029723-A1 | TFLA GENE WHICH CAN DEGRADE TOXOFLAVIN AND ITS CHEMICAL DERIVATIVES AND TRANSGENIC ORGANISMS EXPRESSING TFLA GENE | SNU R&DB Foundation (KR) | 2009-03-04 | — | — | EP | claimed |
| WO-2007148926-A9 | TFLA GENE WHICH CAN DEGRADE TOXOFLAVIN AND ITS CHEMICAL DERIVATIVES AND TRANSGENIC ORGANISMS EXPRESSING TFLA GENE | SNU R&DB FOUNDATION (KR) | 2009-01-29 | — | — | WO | claimed |
| WO-2007148926-A1 | TFLA GENE WHICH CAN DEGRADE TOXOFLAVIN AND ITS CHEMICAL DERIVATIVES AND TRANSGENIC ORGANISMS EXPRESSING TFLA GENE | SNU R & DB FOUNDATION (KR) | 2007-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | NFATC1, CTNNB1, CAMK1D | KDM4C 1037/4885NPC1 4115/4885POLB 1452/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | KDM4C 1734/4885NPC1 4688/4885POLB 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.